Uvax Bio

Uvax Bio is a private, pre-revenue biotech advancing a pipeline of vaccine candidates, with its lead HIV-1 program preparing for a Phase 1 clinical trial sponsored by the NIH. Its core asset is the 1c-SApNP® platform, which utilizes rational antigen design and a multi-layered nanoparticle display to create vaccines with a manufacturing profile akin to proven VLP technologies. The company is backed by Series A funding and over $10M in non-dilutive NIH grants, positioning it to advance high-priority infectious disease programs through early clinical development.

Proprietary 1c-SApNP® (Single-Component Self-Assembling protein Nanoparticle) platform for vaccine development. It combines rational, structure-based antigen design, display of antigens on a multilayered protein nanoparticle (45-70nm), and a simplified one-step expression, three-step purification manufacturing process.

Uvax Bio competes in the challenging HIV vaccine space against entities like IAVI, Moderna (mRNA), and Janssen (viral vector). More broadly, its nanoparticle VLP platform competes with established technologies from GSK, Merck, and Novavax, as well as next-generation platforms from numerous biotechs. Differentiation hinges on the unique combination of rational design, nanoparticle immunogenicity, and simplified manufacturing.